Literature DB >> 34255199

Clinical influence of calcium hydroxide intracanal medications on matrix metalloproteinases and tissue inhibitors of metalloproteinases in apical periodontitis.

Flavia F C Teixeira1, Flavia G R Cardoso1, Nadia S Ferreira1, Ana P M Gomes1, Bruna J M Corazza1, Marcia C Valera1, Frederico C Martinho2.   

Abstract

OBJECTIVES: This study investigated the influence of calcium hydroxide intracanal medications on the levels of metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in apical periodontitis (AP).
MATERIALS AND METHODS: Twenty primarily infected root canals with AP were randomly divided into two groups: Ca(OH)2 + sterile saline solution (SSL) group and Ca(OH)2 + 2% chlorhexidine gel (CHX gel) group. We collected samples from the periradicular tissue fluid (PTF) before (s1) and after 14 days of intracanal medication (s2). MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were measured by ELISA assay.
RESULTS: MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were detected in all PTF samples at s1 and s2 (20/20). At s1, MMP-2 and MMP-9 were detected at higher levels than MMP-1 (p < .05). Higher levels of TIMP-1 than TIMP-2 were found in AP (p < .05). Additionally, we detected higher MMP-1, MMP-2, and MMP-9 over TIMP-1 and TIMP-2 levels in AP (p < .05). At s2, Ca(OH)2 + SSL was as effective as Ca(OH)2 + 2% CHX gel in lowering the levels of MMP-1, MMP-2, and MMP-9 after 14 days of intracanal medication, with no significant difference between them (p > .05). Both Ca(OH) 2 intracanal medications had no significant impact on the levels of TIMP-1 and TIMP-2 (both p > .05). At s2, TIMP-1 levels were higher than TIMP-2 (p < .05). Moreover, there were positive correlations between the levels of MMP-1 and TIMP-1 and MMP-1 and TIMP-2 (p < .05).
CONCLUSIONS: Calcium hydroxide medications effectively lowered the levels of MMP-1, MMP-2, and MMP-9 in periapical tissues after 14 days of treatment, with no difference between them. Moreover, the calcium hydroxide intracanal medications tested here had no impact in TIMP-1 and TIMP-2 in periapical tissues. CLINICAL RELEVANCE: MMPs and TIMPs play an essential role in the degradation of the extracellular matrix. The imbalance MMPs and TIMPs can cause periapical tissue destruction. Therefore, the reestablishment of the balance between activated MMPs and TIMPs with root canal therapy is essential to restore tissue homeostasis.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Calcium hydroxide; Intracanal medication; Matrix metalloproteinase; Root canal

Mesh:

Substances:

Year:  2021        PMID: 34255199     DOI: 10.1007/s00784-021-04042-z

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  54 in total

Review 1.  Tissue inhibitors of metalloproteinases (TIMPs): their biological functions and involvement in oral disease.

Authors:  J Verstappen; J W Von den Hoff
Journal:  J Dent Res       Date:  2006-12       Impact factor: 6.116

Review 2.  Structure and function of matrix metalloproteinases and TIMPs.

Authors:  Hideaki Nagase; Robert Visse; Gillian Murphy
Journal:  Cardiovasc Res       Date:  2006-01-05       Impact factor: 10.787

3.  Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.

Authors:  F X Gomis-Rüth; K Maskos; M Betz; A Bergner; R Huber; K Suzuki; N Yoshida; H Nagase; K Brew; G P Bourenkov; H Bartunik; W Bode
Journal:  Nature       Date:  1997-09-04       Impact factor: 49.962

4.  Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients.

Authors:  T Ingman; T Tervahartiala; Y Ding; H Tschesche; A Haerian; D F Kinane; Y T Konttinen; T Sorsa
Journal:  J Clin Periodontol       Date:  1996-12       Impact factor: 8.728

5.  Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjögren's syndrome.

Authors:  Masumi Asatsuma; Satoshi Ito; Mamoru Watanabe; Hideyuki Takeishi; Shuichi Nomura; Yoko Wada; Masaaki Nakano; Fumitake Gejyo; Atsuko Igarashi
Journal:  Clin Chim Acta       Date:  2004-07       Impact factor: 3.786

6.  Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.

Authors:  Garrett C Durkan; Joyce E Nutt; Colin Marsh; Paul H Rajjayabun; Mary C Robinson; David E Neal; John Lunec; J Kilian Mellon
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

7.  Toll-like receptor activation and mechanical force stimulation promote the secretion of matrix metalloproteinases 1, 3 and 10 of human periodontal fibroblasts via p38, JNK and NF-kB.

Authors:  Rodolfo Assis Lisboa; Marcus Vinícius Andrade; José Renan Cunha-Melo
Journal:  Arch Oral Biol       Date:  2013-01-14       Impact factor: 2.633

8.  A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies.

Authors:  N Fujimoto; J Zhang; K Iwata; T Shinya; Y Okada; T Hayakawa
Journal:  Clin Chim Acta       Date:  1993-10-29       Impact factor: 3.786

Review 9.  Matrix metalloproteinases in immunity.

Authors:  E J Goetzl; M J Banda; D Leppert
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

10.  Effectiveness of calcium hydroxide-based intracanal medication on infectious/inflammatory contents in teeth with post-treatment apical periodontitis.

Authors:  Marlos Barbosa-Ribeiro; Rodrigo Arruda-Vasconcelos; Adriana de-Jesus-Soares; Alexandre Augusto Zaia; Caio Cezar Randi Ferraz; José Flávio Affonso de Almeida; Brenda P F A Gomes
Journal:  Clin Oral Investig       Date:  2018-10-26       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.